The Icahn School of Medicine at Mount Sinai Joins NeuroNEXT Research Network Through Five-Year Grant From the National Institutes of Health
Innovative network designed to increase efficiency of neuroscience clinical trials for brain disorders
The Icahn School of Medicine at Mount Sinai (ISMMS) has joined the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT), a research program that helps streamline phase II clinical trials for brain disorders. NeuroNEXT is supported by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH).
“Earning a place in the NeuroNEXT network enables us to expand the collaborations taking place between basic and clinical brain researchers and experienced clinicians in numerous departments across the Mount Sinai Health System and with partners outside our institution,” says Barbara Vickrey, MD, MPH, Henry P. and Georgette Goldschmidt Professor and System Chair of Neurology. “Through this national network, we can build upon remarkable advances that have been achieved in studying the brain and spinal cord—many developed and put into practice at Mount Sinai—so that we can take what we learn at the bench and translate that knowledge into fundamentally new and improved treatments. We are well positioned to ensure timely, successful execution of these trials and are proud to be partnering with such an excellent cadre of research institutions that share a commitment to collaboration. Through this shared value and robust partnership, we can bring hope to the many patients and families who face devastating neurological conditions.”
Started in 2012 to make neuroscience clinical trials more efficient and to help increase the number of treatments that get into clinical practice, the NeuroNEXT program is designed to encourage collaborations between academic centers, disease foundations, and industry. Through this integrated network, participating academic medical centers will be able to enroll more patients in larger clinical trials and complete them more rapidly than each center could by itself.
Aaron Miller, MD, Professor of Neurology at ISMMS and Director of Clinical Affairs for The Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, and Adilia Hormigo, MD, PhD, Associate Professor of Neurology, Medicine, and Neurosurgery at ISMMS and Director of the Neuro-Oncology Program at The Mount Sinai Hospital, will serve as Principal Investigators of the five-year NIH grant. Nathalie Jette, MD, MSc, Vice Chair for Clinical Research in the Department of Neurology at ISMMS, will serve as the Career Enhancement Director for junior/early stage investigator training for NeuroNEXT projects at Mount Sinai. The grant enables researchers from Mount Sinai to quickly mobilize with a diverse set of clinicians and experts from a wide range of disciplines to expedite clinical research so that treatments can get to patients faster.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.